一直以来，本集团十分重视研发，不断提升研发水平和速度，并视其为可持续发展的基础，加大研发的 资金投入。截至2025年6月30日止6个月，研究与开发成本约31.88亿元，占本集团收入约18.1%，连同已 资本化的研发总开支出在内，约95.7%已计入损益表中。 中国生物制药(01177)发布截至2025年6月30日止6个月的中期业绩，该集团取得收入人民币175.7亿元(单 位下同)，同比增加10.7%;母公司持有人应占溢利33.89亿元，同比增加12.31%;财务报表所示来自持续经 营业务的归属于母公司持有者盈利33.9亿元，同比增加140.2%;基本每股盈利18.82分，拟派发中期股息 每股5港仙。 于报告期内，本集团共有2个创新产品获NMPA批准上市，分别为普坦宁(美洛昔康注射液(II))和安启新 (注射用重组人凝血因子VIIa N01)。2025年上半年，本集团创新产品收入达到78亿元，同比增长 27.2%。除创新产品外，本集团还有5个仿制药获NMPA批准上市，整体仿制药收入在2025年上半年保持 正增长。 ...

格隆汇8月18日丨中国生物制药(01177.HK)发布公告，截至2025年6月30日止六个月，于本期间内，集团 录得收入约人民币175.75亿元，较去年同期增长约10.7%。财务报表所示的来自持续经营业务的归属于 母公司持有者盈利约人民币33.89亿元，较去年增加约140.2%。基于财务报表所示的来自持续经营业务 的归属于母公司持有者盈利计算的每股基本盈利约人民币18.82分，较去年增加约145.7%。财务报表所 示的来自持续经营业务的归属于母公司持有者盈利同比增长主要受惠于本期间收入明显增长及股息收益 和投资公允价值变动收益明显增长。扣除已终止经营业务的归属于母公司持有者应占盈利、应占联营公 司及合营公司盈利及亏损(扣除相关税项及非控制权益)、若干资产及负债的公允价值变动及一次性调整 的减值(扣除相关税项及非控制权益)，流动权益投资的公允价值亏损╱(利润)净额(扣除相关税项及非控 制权益)，股权激励费用(扣除相关税项及非控制权益)，可转换债券债务部份的利息费用及汇兑损失 ╱(收益)等的影响后，归属于母公司持有者的基本溢利(非香港财务报告准则指标)约人民币30.88亿元， 较去年同期大幅增长约101.1%。董 ...

（於開曼群島註冊成立之有限公司） 網站：www.sinobiopharm.com （股票編號：1177） 截至二零二五年六月三十日止六個月之中期業績公告 | 財務摘要 | | | | | --- | --- | --- | --- | | | 截至六月三十日止六個月 | | | | | 二零二五年 | 二零二四年 | 變動 | | | 人民幣億元 | 人民幣億元 | % | | 收入 | 175.7 | 158.7 | +10.7% | | 毛利率(%) | 82.5% | 82.1% | +0.4百分點 | | （附註1） 銷售及管理費用佔收入比率(%) | 42.9% | 43.1% | -0.2百分點 | | 研發費用佔收入比率(%) | 18.1% | 16.2% | +1.9百分點 | | 來自持續經營業務之歸屬於母公司持有者盈利 | | | | | （附註2） 財務報表所示 | 33.9 | 14.1 | +140.2% | | （附註3） 基本溢利 | 30.9 | 15.4 | +101.1% | | （附註4） 創新產品收入 | 78.0 | 61.3 | +27.2% | | 佔收入 | ...

8月18日，中国生物制药(01177)盘中上涨2.05%，截至14:42，报7.98元/股，成交7.44亿元。 中国生物制药有限公司是一家创新研究和研发驱动型的医药集团，其主要业务包括医药研发、智能化生 产以及销售，主要产品包括多种生物药和化学药，特别在肿瘤、肝病、呼吸系统、外科/镇痛四大治疗 领域具有优势。公司自从2000年上市以来，在MSCI全球标准指数、恒生指数等多个指数中成为成分 股，连续六年入选《制药经理人》的"全球制药企业TOP50"，核心企业正大天晴药业集团、北京泰德制 药股份有限公司多年位列中国医药工业企业百强榜，公司产品收入占比逐年提升。 截至2024年年报，中国生物制药营业总收入288.66亿元、净利润35.0亿元。 作者：行情君 8月18日，中国生物制药披露2025财年中报。 本文源自：金融界 ...

(Stock Code: 1177.HK) (RMB bn) 2025 2025 Interim Results Announcement 2025.8.18 Hong Kong CONTENTS Financial Highlights Pipeline Highlights 2 Financial Highlights Both revenue and profit achieved double-digit growth 1.54 3.09 2024 H1 Continuing Operations 2025 H1 Continuing Operations Revenue 15.87 17.57 2024 H1 Continuing Operations 2025 H1 Continuing Operations Profit attributable to owners of the parent (as reported) 1.41 3.39 2024 H1 Continuing Operations 2025 H1 Continuing Operations Profit attributabl ...

Core Viewpoint - China National Pharmaceutical Group (01177) experienced a 3.28% increase in stock price, reaching 7.87 CNY per share with a transaction volume of 300 million CNY as of 10:21 AM on August 15 [1] Group 1: Company Overview - China National Pharmaceutical Group is an innovative research and development-driven pharmaceutical company, focusing on drug research, intelligent manufacturing, and sales [1] - The company specializes in various biological and chemical drugs, particularly excelling in four therapeutic areas: oncology, liver disease, respiratory system, and surgical/pain management [1] - Since its listing in 2000, the company has been included in multiple indices such as the MSCI Global Standard Index and the Hang Seng Index, and has been recognized in the "Top 50 Global Pharmaceutical Companies" by Pharmaceutical Manager for six consecutive years [1] Group 2: Financial Performance - As of the 2024 annual report, the company reported total revenue of 28.866 billion CNY and a net profit of 3.5 billion CNY [1] - The revenue contribution from the company's products has been increasing year by year [1] - The company is set to disclose its mid-year report for the fiscal year 2025 on August 18 [1]

Core Viewpoint - China Biologic Products (01177) has received acceptance for the clinical trial application (IND) of its innovative drug TQB3142, a Bcl-xL PROTAC molecule, from the National Medical Products Administration (NMPA) in China, aimed at treating malignant tumors [1] Group 1: Product Details - TQB3142 targets the degradation of the Bcl-xL protein through the ubiquitin-proteasome system, which alleviates its inhibition on tumor cell apoptosis, thereby activating the Caspase cascade and inducing programmed cell death in tumor cells [1] - Research indicates that TQB3142 demonstrates significant anti-tumor activity in various transplant tumor models and has a lower risk of platelet toxicity compared to similar candidate drugs, offering a better therapeutic window with controllable metabolic risks [1] Group 2: Market Position - Currently, there are no approved Bcl-xL inhibitors available globally, making TQB3142 a novel mechanism anti-tumor drug [1] - The drug's molecular design optimization allows it to maintain degradation activity while reducing blood toxicity risks, potentially providing new treatment options for patients with malignant tumors [1]

Core Viewpoint - China Biopharmaceutical (01177.HK) has received acceptance for the clinical trial application (IND) of its innovative drug TQB3142, a Bcl-xL PROTAC molecule, from the National Medical Products Administration (NMPA) in China, aimed at treating malignant tumors [1] Group 1: Drug Mechanism and Efficacy - TQB3142 targets the degradation of the Bcl-xL protein through the ubiquitin-proteasome system, which alleviates its inhibition on tumor cell apoptosis, thereby activating the Caspase cascade and inducing programmed cell death in tumor cells [1] - The drug has shown significant anti-tumor activity in various transplantation tumor models and has a lower risk of platelet toxicity compared to similar candidate drugs, indicating a better therapeutic window and controllable metabolic risks [1] Group 2: Market Position and Potential - Currently, there are no approved Bcl-xL inhibitors available globally, making TQB3142 a novel mechanism anti-tumor drug [1] - The optimization of molecular design in TQB3142 allows for the maintenance of degradation activity while reducing blood toxicity risks, potentially providing new treatment options for patients with malignant tumors [1]

Core Viewpoint - China Biologic Products (01177) has received acceptance for the clinical trial application (IND) of its innovative drug TQB3142, a Bcl-xL PROTAC molecule, from the National Medical Products Administration (NMPA) in China, aimed at treating malignant tumors [1] Group 1: Drug Mechanism and Efficacy - TQB3142 targets the degradation of the Bcl-xL protein through the ubiquitin-proteasome system, which alleviates its inhibition on tumor cell apoptosis, thereby activating the Caspase cascade and inducing programmed cell death in tumor cells [1] - Research indicates that TQB3142 demonstrates significant anti-tumor activity across various transplant tumor models, with lower platelet toxicity risk compared to similar candidate drugs, offering a better therapeutic window and controllable metabolic risks [1] Group 2: Market Position and Potential - Currently, there are no approved Bcl-xL inhibitors globally, making TQB3142 a novel mechanism anti-tumor drug [1] - The drug's optimized molecular design maintains degradation activity while reducing blood toxicity risks, potentially providing new treatment options for patients with malignant tumors [1]

（於開曼群島註冊成立之有限公司） 網站：www.sinobiopharm.com （股份編號：1177） 自願公告 TQB3142「Bcl-xL PROTAC」臨床試驗申請獲NMPA受理 中國生物製藥有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董事會」）宣佈，本集團自 主研發的創新藥TQB3142「Bcl-xL PROTAC （蛋白降解靶向嵌合體）」的新藥臨床試驗申請(IND)已獲 得中國國家藥品監督管理局(NMPA)受理，擬用於治療惡性腫瘤。 TQB3142是一款靶向降解Bcl-xL蛋白的PROTAC分子，通過泛素－蛋白酶體系統特異性降解Bcl-xL 蛋白，解除其對腫瘤細胞凋亡的抑制，從而激活Caspase級聯反應，誘導腫瘤細胞程序性死亡。研 究顯示，TQB3142在多種移植瘤模型中表現出顯著抑瘤活性，且對血小板毒性風險低於同類候選藥 物，具有更優的治療窗口，代謝風險可控。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 中國生物 ...